This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Body Composition Analysis in Patients Undergoing Chemoembolization

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
ALDO TORRE DELGADILLO, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
ClinicalTrials.gov Identifier:
NCT01777698
First received: January 21, 2013
Last updated: June 7, 2016
Last verified: June 2016
  Purpose

Hepatocellular carcinoma represents 80-90% of primary hepatic malignant tumors. 80% of patients with hepatocellular carcinoma are associated with cirrhosis.

Chemoembolization is a process in which a chemotherapeutic agent is deposited directly into the hepatic tumor where the principal artery is embolized.

Bioelectrical impedance bases its evaluation in a model where the body is conformed by two different compartments: fat mass and fat free mass.

Bioelectrical impedance is complemented by vectorial analysis, which is independent to the state of hydration and is helpful to monitor any changes in corporal composition. It can be used as a control for the interpretation of the bioelectrical impedance.


Condition
Hepatocellular Carcinoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Body Composition Analysis by Bioelectrical Impedance Vector Analysis in Patients With Hepatocellular Carcinoma Undergoing Chemoembolization.

Further study details as provided by ALDO TORRE DELGADILLO, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran:

Primary Outcome Measures:
  • Changes in body composition [ Time Frame: 1 hour before treatment, 2 weeks after treatment, and 1 month after treatment ]
    To evaluate any changes in corporal composition in patients undergoing chemoembolization.


Enrollment: 21
Study Start Date: April 2012
Study Completion Date: March 2016
Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
The patients will be recruited from the Radiology Department of a tertiary care center.
Criteria

Inclusion Criteria:

  • Patients with hepato-renal disease
  • Patients with hepatocellular carcinoma that are put down to radiofrequency ablation
  • Patients with depression or any psiquiatric disease.
  • Patients that don't agree to participate in the project.

Exclusion Criteria:

  • Patients with hepatocellular carcinoma that are put down to radiofrequency ablation
  • Patients with depression or any psiquiatric disease.
  • Patients that don't agree to participate in the project.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01777698

Locations
Mexico
Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán"
Mexico city, Mexico, 14000
Sponsors and Collaborators
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Investigators
Study Chair: Aldo Torre, M.D, M.Sc. Instituto Nacional de Nutrición y Ciencias Médicas "Salvador Zubirán"
  More Information

Responsible Party: ALDO TORRE DELGADILLO, M.D., M.Sc., Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
ClinicalTrials.gov Identifier: NCT01777698     History of Changes
Other Study ID Numbers: QMECR1
Study First Received: January 21, 2013
Last Updated: June 7, 2016

Keywords provided by ALDO TORRE DELGADILLO, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran:
body composition
hepatocellular carcinoma
chemoembolization

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases

ClinicalTrials.gov processed this record on September 21, 2017